Skip to main content
Erschienen in: Current Rheumatology Reports 2/2014

01.02.2014 | CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

The Crystallization of Monosodium Urate

Erschienen in: Current Rheumatology Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Gout is a common crystal-induced arthritis, in which monosodium urate (MSU) crystals precipitate within joints and soft tissues and elicit an inflammatory response. The causes of elevated serum urate and the inflammatory pathways activated by MSU crystals have been well studied, but less is known about the processes leading to crystal formation and growth. Uric acid, the final product of purine metabolism, is a weak acid that circulates as the deprotonated urate anion under physiologic conditions, and combines with sodium ions to form MSU. MSU crystals are known to have a triclinic structure, in which stacked sheets of purine rings form the needle-shaped crystals that are observed microscopically. Exposed, charged crystal surfaces are thought to allow for interaction with phospholipid membranes and serum factors, playing a role in the crystal-mediated inflammatory response. While hyperuricemia is a clear risk factor for gout, local factors have been hypothesized to play a role in crystal formation, such as temperature, pH, mechanical stress, cartilage components, and other synovial and serum factors. Interestingly, several studies suggest that MSU crystals may drive the generation of crystal-specific antibodies that facilitate future MSU crystallization. Here, we review MSU crystal biology, including a discussion of crystal structure, effector function, and factors thought to play a role in crystal formation. We also briefly compare MSU biology to that of uric acid stones causing nephrolithasis, and consider the potential treatment implications of MSU crystal biology.
Literatur
1.
Zurück zum Zitat Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part II. Arthritis Rheum. 2008;58(1):26–35.PubMedCentralPubMedCrossRef Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part II. Arthritis Rheum. 2008;58(1):26–35.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):21.CrossRef Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):21.CrossRef
4.
Zurück zum Zitat Burns CM, Wortmann RL. Disorders of purine and pyramidine metabolism. In: Fauci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s Priciples of Internal Medicine. New York: McGraw-Hill; 2012. Burns CM, Wortmann RL. Disorders of purine and pyramidine metabolism. In: Fauci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s Priciples of Internal Medicine. New York: McGraw-Hill; 2012.
5.
Zurück zum Zitat Wu XW et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1):78–84.PubMedCrossRef Wu XW et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1):78–84.PubMedCrossRef
7.
Zurück zum Zitat Oda M et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19(5):640–53.PubMedCrossRef Oda M et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19(5):640–53.PubMedCrossRef
8.
Zurück zum Zitat Huang HY et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843–7.PubMedCrossRef Huang HY et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum. 2005;52(6):1843–7.PubMedCrossRef
9.
Zurück zum Zitat Sebesta I. Genetic disorders resulting in hyper- or hypouricemia. Adv Chronic Kidney Dis. 2012;19(6):398–403.PubMedCrossRef Sebesta I. Genetic disorders resulting in hyper- or hypouricemia. Adv Chronic Kidney Dis. 2012;19(6):398–403.PubMedCrossRef
10.
Zurück zum Zitat Busso N, So A. Microcrystals as DAMPs and their role in joint inflammation. Rheumatology (Oxford). 2012;51(7):1154–60.CrossRef Busso N, So A. Microcrystals as DAMPs and their role in joint inflammation. Rheumatology (Oxford). 2012;51(7):1154–60.CrossRef
11.
Zurück zum Zitat Martinon F et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.PubMedCrossRef Martinon F et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.PubMedCrossRef
12.
Zurück zum Zitat Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986;83(22):8749–53.PubMedCentralPubMedCrossRef Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986;83(22):8749–53.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1979;91(1):56–7.PubMedCrossRef Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1979;91(1):56–7.PubMedCrossRef
14.
Zurück zum Zitat Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501–5.PubMed Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501–5.PubMed
15.
Zurück zum Zitat Hall AP et al. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967;42(1):27–37.PubMedCrossRef Hall AP et al. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med. 1967;42(1):27–37.PubMedCrossRef
16.
Zurück zum Zitat Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287–9.PubMedCrossRef Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287–9.PubMedCrossRef
17.
Zurück zum Zitat Mandel NS, Mandel GS. Monosodium urate monohydrate, the gout culprit. J Am Chem Soc. 1976;98(8):2319–23.PubMedCrossRef Mandel NS, Mandel GS. Monosodium urate monohydrate, the gout culprit. J Am Chem Soc. 1976;98(8):2319–23.PubMedCrossRef
18.
Zurück zum Zitat Frincu MC, Fogarty CE, Swift JA. Epitaxial relationships between uric acid crystals and mineral surfaces: a factor in urinary stone formation. Langmuir. 2004;20(16):6524–9.PubMedCrossRef Frincu MC, Fogarty CE, Swift JA. Epitaxial relationships between uric acid crystals and mineral surfaces: a factor in urinary stone formation. Langmuir. 2004;20(16):6524–9.PubMedCrossRef
19.
Zurück zum Zitat •• Perrin CM et al. Monosodium urate monohydrate crystallization. CrystEngComm. 2011;13(4):1111–7. Modern-day work in which in situ atomic force microscopy and dynamic light scattering were used to elucidate the growth of monosodium urate crystals on a molecular level.CrossRef •• Perrin CM et al. Monosodium urate monohydrate crystallization. CrystEngComm. 2011;13(4):1111–7. Modern-day work in which in situ atomic force microscopy and dynamic light scattering were used to elucidate the growth of monosodium urate crystals on a molecular level.CrossRef
20.
Zurück zum Zitat Ortiz-Bravo E, Sieck MS, Schumacher Jr HR. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993;36(9):1274–85.PubMedCrossRef Ortiz-Bravo E, Sieck MS, Schumacher Jr HR. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993;36(9):1274–85.PubMedCrossRef
21.
Zurück zum Zitat Cherian PV, Schumacher Jr HR. Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout. Ultrastruct Pathol. 1986;10(3):209–19.PubMedCrossRef Cherian PV, Schumacher Jr HR. Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout. Ultrastruct Pathol. 1986;10(3):209–19.PubMedCrossRef
22.
Zurück zum Zitat Kozin F, McCarty DJ. Molecular orientation of immunoglobulin G adsorbed to microcrystalline monosodium urate monohydrate. J Lab Clin Med. 1980;95(1):49–58.PubMed Kozin F, McCarty DJ. Molecular orientation of immunoglobulin G adsorbed to microcrystalline monosodium urate monohydrate. J Lab Clin Med. 1980;95(1):49–58.PubMed
23.
Zurück zum Zitat Terkeltaub R et al. Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. Arthritis Rheum. 1983;26(6):775–83.PubMedCrossRef Terkeltaub R et al. Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. Arthritis Rheum. 1983;26(6):775–83.PubMedCrossRef
24.
Zurück zum Zitat Mullin JW. Nucleation In Crystallization. Oxford: Butterworth-Heinemann; 1993. p. 172–201. Mullin JW. Nucleation In Crystallization. Oxford: Butterworth-Heinemann; 1993. p. 172–201.
25.
Zurück zum Zitat Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42 Suppl 1:12–5.PubMedCrossRef Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42 Suppl 1:12–5.PubMedCrossRef
26.
Zurück zum Zitat Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–5.PubMedCrossRef Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–5.PubMedCrossRef
27.
Zurück zum Zitat Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum. 1965;8(6):1123–33.PubMedCrossRef Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum. 1965;8(6):1123–33.PubMedCrossRef
28.
Zurück zum Zitat Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189–92.PubMedCrossRef Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189–92.PubMedCrossRef
29.
Zurück zum Zitat Wilcox WR et al. Solubility of uric acid and monosodium urate. Med Biol Eng. 1972;10(4):522–31.PubMedCrossRef Wilcox WR et al. Solubility of uric acid and monosodium urate. Med Biol Eng. 1972;10(4):522–31.PubMedCrossRef
30.
Zurück zum Zitat Wilcox WR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis. 1975;34(4):332–9.PubMedCrossRef Wilcox WR, Khalaf AA. Nucleation of monosodium urate crystals. Ann Rheum Dis. 1975;34(4):332–9.PubMedCrossRef
31.
33.
Zurück zum Zitat McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis. 1991;50(8):558–61.PubMedCrossRef McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis. 1991;50(8):558–61.PubMedCrossRef
34.
Zurück zum Zitat Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37 degrees c. Arthritis Rheum. 1980;23(5):574–80.PubMedCrossRef Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37 degrees c. Arthritis Rheum. 1980;23(5):574–80.PubMedCrossRef
35.
Zurück zum Zitat Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45(10):858–64.PubMedCrossRef Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45(10):858–64.PubMedCrossRef
36.
Zurück zum Zitat Laurent TC. Solubility of Sodium Urate in the Presence of Chondroitin-4-Sulphate. Nature. 1964;202:1334.PubMedCrossRef Laurent TC. Solubility of Sodium Urate in the Presence of Chondroitin-4-Sulphate. Nature. 1964;202:1334.PubMedCrossRef
37.
Zurück zum Zitat • Pascual E, Martinez A, Ordonez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine. 2013;80(1):1–4. A recent review that summarizes information gleaned from current imaging of gouty joints, and a hypothesis regarding what this may teach us about monosodium urate crystallization.PubMedCrossRef • Pascual E, Martinez A, Ordonez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine. 2013;80(1):1–4. A recent review that summarizes information gleaned from current imaging of gouty joints, and a hypothesis regarding what this may teach us about monosodium urate crystallization.PubMedCrossRef
38.
Zurück zum Zitat Katz WA. Role of proteoglycans in the development of gouty arthritis. In: Weiner IM, Kelley WN, editors. Handbook of Experimental Pharmacology. New York: Springer; 1978. p. 347–64. Katz WA. Role of proteoglycans in the development of gouty arthritis. In: Weiner IM, Kelley WN, editors. Handbook of Experimental Pharmacology. New York: Springer; 1978. p. 347–64.
39.
Zurück zum Zitat Kippen I et al. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974;33(4):313–7.PubMedCrossRef Kippen I et al. Factors affecting urate solubility in vitro. Ann Rheum Dis. 1974;33(4):313–7.PubMedCrossRef
40.
Zurück zum Zitat Perl-Treves D, Addadi L. A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization. Proc R Soc Lond B Biol Sci. 1988;235(1279):145–59.PubMedCrossRef Perl-Treves D, Addadi L. A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallization. Proc R Soc Lond B Biol Sci. 1988;235(1279):145–59.PubMedCrossRef
41.
Zurück zum Zitat Kaneko K, Maru M. Determination of urate crystal formation using flow cytometry and microarea X-ray diffractometry. Anal Biochem. 2000;281(1):9–14.PubMedCrossRef Kaneko K, Maru M. Determination of urate crystal formation using flow cytometry and microarea X-ray diffractometry. Anal Biochem. 2000;281(1):9–14.PubMedCrossRef
42.
Zurück zum Zitat Kam M et al. Antibodies against crystals. Faseb J. 1992;6(8):2608–13.PubMed Kam M et al. Antibodies against crystals. Faseb J. 1992;6(8):2608–13.PubMed
43.
Zurück zum Zitat Kam M et al. Specificity in the recognition of crystals by antibodies. J Mol Recognit. 1994;7(4):257–64.PubMedCrossRef Kam M et al. Specificity in the recognition of crystals by antibodies. J Mol Recognit. 1994;7(4):257–64.PubMedCrossRef
44.
45.
Zurück zum Zitat Terkeltaub R et al. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum. 1986;29(3):363–70.PubMedCrossRef Terkeltaub R et al. Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. Arthritis Rheum. 1986;29(3):363–70.PubMedCrossRef
46.
Zurück zum Zitat Scanu A et al. High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther. 2010;12(1):11.CrossRef Scanu A et al. High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther. 2010;12(1):11.CrossRef
47.
Zurück zum Zitat McGill NW, Hayes A, Dieppe PA. Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol. 1992;21(5):215–9.PubMedCrossRef McGill NW, Hayes A, Dieppe PA. Morphological evidence for biological control of urate crystal formation in vivo and in vitro. Scand J Rheumatol. 1992;21(5):215–9.PubMedCrossRef
48.
Zurück zum Zitat Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13(2):146–53.PubMedCrossRef Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13(2):146–53.PubMedCrossRef
49.
Zurück zum Zitat Howard RG et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: Concordance between readers. Arthritis Care & Research. 2011;63(10):1456–62.CrossRef Howard RG et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: Concordance between readers. Arthritis Care & Research. 2011;63(10):1456–62.CrossRef
50.
Zurück zum Zitat Hesse A et al. Uric acid dihydrate as urinary calculus component. Invest Urol. 1975;12(5):405–9.PubMed Hesse A et al. Uric acid dihydrate as urinary calculus component. Invest Urol. 1975;12(5):405–9.PubMed
51.
Zurück zum Zitat Sakhaee K et al. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab. 1987;65(5):974–9.PubMedCrossRef Sakhaee K et al. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab. 1987;65(5):974–9.PubMedCrossRef
52.
Zurück zum Zitat Asplin JR. Uric acid stones. Semin Nephrol. 1996;16(5):412–24.PubMed Asplin JR. Uric acid stones. Semin Nephrol. 1996;16(5):412–24.PubMed
53.
Zurück zum Zitat Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62(3):971–9.PubMedCrossRef Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62(3):971–9.PubMedCrossRef
54.
Zurück zum Zitat Pak CY et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60(2):757–61.PubMedCrossRef Pak CY et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60(2):757–61.PubMedCrossRef
55.
Zurück zum Zitat Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271–8.PubMedCrossRef Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271–8.PubMedCrossRef
56.
Zurück zum Zitat Ettinger B et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9.PubMedCrossRef Ettinger B et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9.PubMedCrossRef
57.
Zurück zum Zitat Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96.PubMedCrossRef Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96.PubMedCrossRef
58.
Zurück zum Zitat Pak CY et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59(3):426–31.PubMedCentralPubMedCrossRef Pak CY et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59(3):426–31.PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056–8.PubMedCrossRef Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056–8.PubMedCrossRef
60.
Zurück zum Zitat Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495–503.PubMedCrossRef Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495–503.PubMedCrossRef
61.
Zurück zum Zitat Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008;20(2):167–72.PubMedCrossRef Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008;20(2):167–72.PubMedCrossRef
62.
Zurück zum Zitat Rimer JD et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science. 2010;330(6002):337–41.PubMedCrossRef Rimer JD et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science. 2010;330(6002):337–41.PubMedCrossRef
Metadaten
Titel
The Crystallization of Monosodium Urate
Publikationsdatum
01.02.2014
Erschienen in
Current Rheumatology Reports / Ausgabe 2/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0400-9

Weitere Artikel der Ausgabe 2/2014

Current Rheumatology Reports 2/2014 Zur Ausgabe

ANTIPHOSPHOLIPID SYNDROME (D ERKAN, SECTION EDITOR)

Renal Involvement in Antiphospholipid Syndrome

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

A Surprising Role for Uric Acid: The Inflammatory Malaria Response

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Anti-Interleukin-1 Therapy in the Management of Gout

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Uric Acid and Xanthine Oxidoreductase in Wound Healing

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.